Actinium Pharmaceuticals Inc (ATNM)
9.80
-0.05
(-0.51%)
USD |
NYAM |
May 17, 16:00
9.75
-0.05
(-0.51%)
After-Hours: 20:00
Actinium Pharmaceuticals Research and Development Expense (Annual): 38.67M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 38.67M |
| December 31, 2022 | 23.14M |
| December 31, 2021 | 18.03M |
| December 31, 2020 | 16.08M |
| December 31, 2019 | 16.55M |
| December 31, 2018 | 17.09M |
| December 31, 2017 | 17.72M |
| Date | Value |
|---|---|
| December 31, 2016 | 17.83M |
| December 31, 2015 | 13.50M |
| December 31, 2014 | 12.27M |
| December 31, 2013 | 3.109M |
| December 31, 2012 | 3.440M |
| December 31, 2011 | 0.3238M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
16.08M
Minimum
2020
38.67M
Maximum
2023
22.49M
Average
18.03M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Perspective Therapeutics Inc | 21.31M |
| Eli Lilly and Co | 9.313B |
| Cellectar Biosciences Inc | 28.21M |
| Outlook Therapeutics Inc | 26.45M |
| Bristol-Myers Squibb Co | 9.299B |